Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease

Journal of Veterinary Diagnostic Investigation

Volumn 14, Issue 5, 2002, Pages 389-395

  Shryock, Thomas R ^a   Staples, J Mitchell ^a   DeRosa, David C ^a  

^a ELANCO ANIMAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; ERYTHROMYCIN; MACROLIDE; TILMICOSIN; TYLOSIN;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL; ANIMAL DISEASE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DIFFUSION; DRUG EFFECT; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PASTEURELLA MULTOCIDA; SWINE; SWINE DISEASE;

ACTINOBACILLUS INFECTIONS; ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMALS; ANTI-BACTERIAL AGENTS; DIFFUSION; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PASTEURELLA INFECTIONS; PASTEURELLA MULTOCIDA; SWINE; SWINE DISEASES; TYLOSIN;

EID: 1842866082     PISSN: 10406387     EISSN: None     Source Type: Journal    
DOI: 10.1177/104063870201400505     Document Type: Article

References (30)

1. Blackall PJ, Asakawa T, Graydon RJ, et al.: 1995, In vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. Aust Vet J 72:35-36.
2. Bradford PA, Sanders CC: 1992, Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam. Antirnicrob Agents Chemother 36:394-400.
3. Debono M, Willard KE, Kirst HA. et al : 1989, Synthesis and antimicrobial evaluation of 20-deoxo-20-(3,5-dimethylpiperidin-1-y1)desmycosin. J Antibiot 42:1253-1267.
4. DeRosa DC, Veenhuizen MF, Bade DJ. Shryock TR: 2000, In vitro susceptibility of porcine respiratory pathogens to tilmicosin. J Vet Diagn Invest 12:541-546.
5. Diarra MS, Malouin F, Jacques M: 1999, Postantibiotic and physiological effects of tilmicosin. tylosin and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens. Int J Antimicrob Agents 12:229-237.
6. Fodor L, Varga J, Gallowitsch F, et al.: 1993, Treatment of calf pneumonia with tilmicosm. Acta Vet Hung 41:41-49.
7. Gavan TL, Jones RN, Barry AL: 1980, Evaluation of the Sensititre system for quantitative antimicrobial drug susceptibility testing: a collaborative study. Antimicrob Agents Chemother 17: 464-469.
8. Gladue RP, Bright GM, Isaacson RE, Newborg MF: 1989, In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells. possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33:277-282.
9. Gorham PE, Carroll LH, McAskill JW, et al.: 1990, Tilmicosin as a single injection treatment for respiratory disease of feedlot cattle. Can Vet J 31:826-829.
10. Inamoto T, Dikuchi K, Iijima H, et al.: 1994, Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine. J Vet Med Sci 56:917-921.
11. Jordan WH, Byrd RA, Cochrane RL, et al.: 1993, A review of the toxicology of the antibiotic Micotil® 300. Vet Hum Toxicol 35:151-157.
12. Kirst H: 1997. Macrolide antibiotics in food-animal health. Exp Opin Invest Drugs 6:103-117.
13. Laven R, Andrews AH: 1991. Long-acting antibiotic formulations in the treatment of calf pneumonia: a comparative study of tilmicosin and oxytetracycline. Vet Rec 129:109-111.
14. Lechtenberg KF, Shryock TR. Moore G: 1994, Characterization of an Actinobacillus pleuropneumoniae seeder pig challenge-exposure model. Am J Vet Res 55:1703-1709.
15. Merrill JK, Tonkinson LV: 1989, The effectiveness of Micotil for the treatment of bovine respiratory disease. Bovine Pract 24: 26-28.
16. Moore GM, Basson RP, Tonkinson LV: 1996, Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Am J Vet Res 57:224-228.
17. Morck D, Merrill JK, Thorlakson BE: 1993, Prophylactic efficacy of tilmicosin for bovine respiratory tract disease. J Am Vet Med Assoc 202:273-277.
18. Moore GM, Mowrey DH, Tonkinson LV, et al.: 1996, Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Am J Vet Res 57:220-223.
19. NCCLS: 2001, Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents: approved guideline. NCCLS document M37-A. NCCLS, Wayne, PA.
20. NCCLS: 2001. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard. NCCLS document M31-A. NCCLS. Wayne, PA.
21. NCCLS: 2001. Performance standards for antimicrobial susceptibility testing; eleventh informational supplement. NCCLS document M100-S11. NCCLS, Wayne, PA.
22. Norcia LJL, Silvia AM, Hayashi SF: 1999, Studies on time-kill kinetics of different classes of antibiotics against veterinary pathogenic bacteria including Pasleurella, Actinabacillus, and Escherichia coll. J Antibiot 52:52-60.
23. Ose EE: 1987, In vitro antibacterial properties of EL-870, a new semi synthetic macrolide antibiotic. J Antibiot 15:190-194.
24. Prescott JF: 2000, Lincosamides, macrolides, and pleuromutilins. In: Antimicrobial therapy in veterinary medicine, eds. Prescott JF, Baggot JD, Walker RD, 3rd ed., pp. 229-262. Iowa State University Press, Ames, IA.
25. Salmon S, Watts JL, Huffman LJ, et al.: 1995, Comparison of MICs of ceftiofur and other antimicrobial agents against bacterial pathogens of swine from the United States. Canada, and Denmark. J Clin Microbiol 33:2435-2444.
26. Scorneaux B, Shryock TR: 1998, Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes. J Vet Pharm Ther 21:257-268.
27. Shryock TR, White DW, Staples JM. Werner CS: 1996, Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pusteurella spp. associated with bovine respiratory disease J Vet Diagn Invest 8 337-344.
28. Shryock TR, White DW, Werner CS, Staples JM: 1995, Proposed quality control guidelines for antimicrobial susceptibility tests using tilmicosin. J Clin Microbiol 33:331-335.
29. Van Koevering MT, Smith RA, Gill DRI, Owens FN: 1992, Effects of tilmicosin or ceftiofur sodium on health and performance of shipping stressed calves J Anim Sci 70:90.
30. Woolfrey BF, Fox JM, Quall CO, Lally RT: 1983, Error rates associated with the use of recently proposed breakpoints for testing Pseudomonas aeruginosa versus gentamicin, tobramycin and amikacin by the standardized disk agar diffusion test. Antimicrob Agents Chemother 24:764-770.